Debt instrument, covenant compliance, minimum percentage of revolving credit commitments.

No definition available.

Name:	hznp_DebtInstrumentCovenantComplianceMinimumPercentageOfRevolvingCreditCommitments
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Debt instrument LIBOR floor rate.

+ References

No definition available.

+ Details

Name:	hznp_DebtInstrumentLIBORFloorRate
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Debt instrument leverage ratio.

+ References

No definition available.

+ Details

Name:	hznp_DebtInstrumentLeverageRatio
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Decrease in percentage on excess cash flow for mandatory prepayments of debt.

+ References

No definition available.

+ Details

Name:	hznp_DecreaseInPercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

First lien leverage ratio.

+ References

No definition available.

+ Details

Name:	hznp_FirstLienLeverageRatio
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line of credit facility additional borrowing capacity.

+ References

No definition available.

+ Details

Name:	hznp_LineOfCreditFacilityAdditionalBorrowingCapacity
Namespace Prefix:	hznp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line of credit facility, expiration month and year.

+ References

No definition available.

+ Details

Name:	hznp_LineOfCreditFacilityExpirationMonthAndYear
Namespace Prefix:	hznp_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage on excess cash flow for mandatory prepayments of debt.

+ References

No definition available.

+ Details

Name:	hznp_PercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage on first lien leverage ratio for mandatory prepayments of debt.

+ References

No definition available.

+ Details

Name:	hznp_PercentageOnFirstLienLeverageRatioForMandatoryPrepaymentsOfDebt
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduced margin based on leverage ratio.

+ References

No definition available.

+ Details

Name:	hznp_ReducedMarginBasedOnLeverageRatio
Namespace Prefix:	hznp_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

+ Details

Name:	us-gaap_DebtInstrumentCarryingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69C
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1D
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611

+ Details

Name:	us-gaap_DebtInstrumentFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Nominal or face amount used to calculate payment on derivative.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

+ Details

Name:	us-gaap_DerivativeNotionalAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.

+ References

+ Details

Name:	us-gaap_LineOfCreditFacilityInterestRateDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_LongTermDebtPercentageBearingVariableInterestRate
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585

+ Details

Name:	us-gaap_RepaymentsOfSecuredDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_LongtermDebtTypeAxis=hznp_TermLoanFacilityDueTwentyTwentyEightMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=hznp_TermLoanFacilityDueTwentyTwentySixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VariableRateAxis=us-gaap_BaseRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=hznp_RefinancingLoansMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=hznp_CreditAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=hznp_HorizonPharmaSubsidiariesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=hznp_HorizonTherapeuticsUSAIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=hznp_NewIncrementalRevolvingCommitmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=hznp_LetterOfCreditSubFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=hznp_HyperionTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=hznp_UnderwrittenPublicOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Debt Agreements - Term Loan Facility and Revolving Credit Facility - Additional Information (Detail) - USD ($)				12 Months Ended
	Mar. 15, 2021	Dec. 18, 2019	Mar. 11, 2019	Dec. 31, 2022	Apr. 25, 2022	Dec. 31, 2021	Jul. 16, 2019
Debt Instrument [Line Items]
Outstanding principal amount				$ 2,590,026,000		$ 2,606,026,000	$ 625,000,000.0
Derivative, Notional Amount				800,000,000.0	$ 800,000,000.0
2028 Term Loans [Member]
Debt Instrument [Line Items]
Outstanding principal amount				$ 1,572,000,000		1,588,000,000
Debt instrument, variable interest rate				6.19%
Debt instrument, effective interest rate				6.42%
2026 Term Loans [Member]
Debt Instrument [Line Items]
Outstanding principal amount				$ 418,026,000		$ 418,026,000
LIBOR floor rate		0.00%
Debt instrument variable rate		2.25%
Interest rate description				The 2026 Term Loans were incurred as a separate new class of term loans under the Credit Agreement with substantially the same terms as the previously outstanding senior secured term loans incurred on May 22, 2019 (the “Refinanced Loans”) to effectuate a repricing of the Refinanced Loans. The Borrower used the proceeds of the 2026 Term Loans to repay the Refinanced Loans, which totaled approximately $418.0 million. The 2026 Term Loans bear interest at a rate, at the Borrower’s option, equal to LIBOR plus 2.25% per annum (subject to a 0.00% LIBOR floor) or the adjusted base rate plus 1.25% per annum, with a step-down to LIBOR plus 2.00% per annum or the adjusted base rate plus 1.00% per annum at the time the Company’s leverage ratio is less than or equal to 2.00 to 1.00.
Maturity date of debt instrument		May 22, 2026
Debt instrument, variable interest rate				6.44%
Debt instrument, effective interest rate				6.72%
2026 Term Loans [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		2.00%
2026 Term Loans [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument leverage ratio		2.00%
2026 Term Loans [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument leverage ratio		1.00%
2026 Term Loans [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		1.25%
2026 Term Loans [Member] \| Base Rate [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		1.00%
Refinancing Loans [Member]
Debt Instrument [Line Items]
Line of credit facility borrowing capacity		$ 418,000,000.0
Refinancing Loans [Member] \| 2028 Term Loans [Member]
Debt Instrument [Line Items]
LIBOR floor rate	0.50%
Debt instrument variable rate	2.00%
Interest rate description				The 2028 Term Loans were incurred as a separate class of term loans under the Credit Agreement with substantially the same terms of the 2026 Term Loans. The Borrower used the proceeds of the 2028 Term Loans to fund a portion of the consideration payable in the acquisition of Viela. The 2028 Term Loans bear interest at a rate, at Borrower’s option, equal to LIBOR, plus 2.00% per annum (subject to a 0.50% LIBOR floor) or the adjusted base rate plus 1.00% per annum, with a step-down to LIBOR plus 1.75% per annum or the adjusted base rate plus 0.75% per annum at the time the Company’s leverage ratio is less than or equal to 2.00 to 1.00. The adjusted base rate is defined as the greatest of (a) LIBOR (using one-month interest period) plus 1.00%, (b) the prime rate, (c) the federal funds rate plus 0.50%, and (d) 1.00%.
Refinancing Loans [Member] \| 2028 Term Loans [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Debt instrument variable rate	1.75%
Refinancing Loans [Member] \| 2028 Term Loans [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument leverage ratio	2.00%
Refinancing Loans [Member] \| 2028 Term Loans [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument leverage ratio	1.00%
Refinancing Loans [Member] \| 2028 Term Loans [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt instrument variable rate	1.00%
Refinancing Loans [Member] \| 2028 Term Loans [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Debt instrument variable rate	0.75%
2026 Term Loans [Member]
Debt Instrument [Line Items]
LIBOR floor rate		0.00%
Interest rate description				he loans under the Revolving Credit Facility bear interest, at the Borrower’s option, at a rate equal to either LIBOR plus an applicable margin of 2.25% per annum (subject to a LIBOR floor of 0.00%), or the adjusted base rate plus 1.25% per annum, with a step-down to LIBOR plus 2.00% per annum or the adjusted base rate plus 1.00% per annum at the time the Company’s leverage ratio is less than or equal to 2.00 to 1.00.
Minimum percentage of total commitments				25.00%
2026 Term Loans [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Leverage ratio less than applicable margin		1.00%
2026 Term Loans [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Leverage ratio less than applicable margin		2.00%
2026 Term Loans [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		2.25%
2026 Term Loans [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		2.00%
2026 Term Loans [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		1.25%
2026 Term Loans [Member] \| Base Rate [Member] \| Scenario, Plan [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		1.00%
Credit Agreement [Member]
Debt Instrument [Line Items]
Proceeds from debt issuances, percentage on excess cash flow		50.00%
Proceeds from debt issuances, reduction percentage on excess cash flow		25.00%
Proceeds from debt issuances, percentage on first lien leverage ratio		0.00%
Credit agreement, description				The Borrower is permitted to make voluntary prepayments of the loans under the Credit Agreement at any time without payment of a premium. The Borrower is required to make mandatory prepayments of loans under the Credit Agreement (without payment of a premium) with (a) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (b) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions), (c) net cash proceeds from issuances of debt (other than certain permitted debt), and (d) 50% of the Company’s excess cash flow (subject to a decrease to 25% or 0% if the Company’s first lien leverage ratio is less than 2.25:1 or 1.75:1, respectively). The 2028 Term Loans will amortize in equal quarterly installments in an aggregate annual amount equal to 1% of the original principal amount thereof, with any remaining balance payable on March 15, 2028, the final maturity date of the 2028 Term Loans. The principal amount of the 2026 Term Loans is due and payable on May 22, 2026, the final maturity date of the 2026 Term Loans.
Credit Agreement [Member] \| Horizon Pharma Subsidiaries [Member]
Debt Instrument [Line Items]
Cut off percentage for defining limited liability subsidiaries, portion of capital stock held maximum		65.00%
Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
First lien leverage ratio		175.00%
Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
First lien leverage ratio		225.00%
Horizon Therapeutics USA, Inc. [Member] \| 2028 Term Loans [Member]
Debt Instrument [Line Items]
Outstanding principal amount	$ 1,600,000,000
Horizon Therapeutics USA, Inc. [Member] \| 2026 Term Loans [Member]
Debt Instrument [Line Items]
Line of credit facility borrowing capacity	$ 418,000,000.0
Horizon Therapeutics USA, Inc. [Member] \| New Incremental Revolving Commitments [Member]
Debt Instrument [Line Items]
Aggregate principal amount			$ 200,000,000.0
Line of credit facility additional borrowing capacity			$ 275,000,000.0
Line of credit facility termination period			2024-03
Horizon Therapeutics USA, Inc. [Member] \| Letter of Credit Sub-facility [Member]
Debt Instrument [Line Items]
Line of credit facility additional borrowing capacity			$ 50,000,000.0
Hyperion Therapeutics, Inc. [Member] \| 2028 Term Loans [Member] \| Underwritten Public Offering
Debt Instrument [Line Items]
Debt instrument, fair value				$ 1,570,000,000.0
Hyperion Therapeutics, Inc. [Member] \| 2026 Term Loans [Member] \| Underwritten Public Offering
Debt Instrument [Line Items]
Debt instrument, fair value				$ 417,500,000